ARTICLE | Company News
MDRNA metabolic, cancer, inflammation news
August 11, 2008 7:00 AM UTC
As part of its previously announced change in focus from intranasal drug delivery to RNAi-based therapeutics, MDRNA will reduce headcount by 23 (29%) to about 55. The cuts come primarily from intranas...